CONTEXT: The impact of HIV infection and exposure to antiretroviral therapy on the development of subclinical atherosclerosis is incompletely understood. OBJECTIVE: To compare intima-media thickness (IMT) of the carotid artery between HIV-infected subjects receiving protease inhibitor-containing regimens and subjects not receiving these regimens and to compare differences in the IMT of the carotid artery between HIV-infected subjects and HIV-uninfected subjects. METHODS: A prospective matched cohort study in university-based outpatient clinics. Groups of three individuals (triads) matched on the following characteristics were enrolled: age, sex, race/ethnicity, smoking status, blood pressure and menopausal status. Group 1, HIV-infected subjects with continuous use of protease inhibitor (PI) therapy for > or = 2 years; group 2, HIV-infected subjects without prior PI use; and group 3: HIV-uninfected. Ultrasonographers at six sites sent standardized ultrasound images to a central reading site for carotid IMT measurements. Carotid IMT was compared within the HIV-infected groups (1 and 2) and between the HIV-infected and uninfected groups in a matched analysis. RESULTS: One hundred and thirty-four individuals were enrolled in 45 triads. The median IMT in groups 1, 2 and 3 was 0.690, 0.712 and 0.698 mm, respectively. There were no statistically significant differences in IMT between groups 1 and 2, or in the combined HIV groups compared with the HIV uninfected group. Significant predictors of carotid IMT in a multivariate model included high-density lipoprotein (HDL) cholesterol, the interaction of HDL cholesterol and triglycerides, age and body mass index. CONCLUSIONS: We found no association between PI inhibitor exposure or HIV infection and carotid IMT.
CONTEXT: The impact of HIV infection and exposure to antiretroviral therapy on the development of subclinical atherosclerosis is incompletely understood. OBJECTIVE: To compare intima-media thickness (IMT) of the carotid artery between HIV-infected subjects receiving protease inhibitor-containing regimens and subjects not receiving these regimens and to compare differences in the IMT of the carotid artery between HIV-infected subjects and HIV-uninfected subjects. METHODS: A prospective matched cohort study in university-based outpatient clinics. Groups of three individuals (triads) matched on the following characteristics were enrolled: age, sex, race/ethnicity, smoking status, blood pressure and menopausal status. Group 1, HIV-infected subjects with continuous use of protease inhibitor (PI) therapy for > or = 2 years; group 2, HIV-infected subjects without prior PI use; and group 3: HIV-uninfected. Ultrasonographers at six sites sent standardized ultrasound images to a central reading site for carotid IMT measurements. Carotid IMT was compared within the HIV-infected groups (1 and 2) and between the HIV-infected and uninfected groups in a matched analysis. RESULTS: One hundred and thirty-four individuals were enrolled in 45 triads. The median IMT in groups 1, 2 and 3 was 0.690, 0.712 and 0.698 mm, respectively. There were no statistically significant differences in IMT between groups 1 and 2, or in the combined HIV groups compared with the HIV uninfected group. Significant predictors of carotid IMT in a multivariate model included high-density lipoprotein (HDL) cholesterol, the interaction of HDL cholesterol and triglycerides, age and body mass index. CONCLUSIONS: We found no association between PI inhibitor exposure or HIV infection and carotid IMT.
Authors: K Mulligan; C Grunfeld; V W Tai; H Algren; M Pang; D N Chernoff; J C Lo; M Schambelan Journal: J Acquir Immune Defic Syndr Date: 2000-01-01 Impact factor: 3.731
Authors: H K Berthold; K G Parhofer; M M Ritter; M Addo; J C Wasmuth; K Schliefer; U Spengler; J K Rockstroh Journal: J Intern Med Date: 1999-12 Impact factor: 8.989
Authors: H N Hodis; W J Mack; R A Lobo; D Shoupe; A Sevanian; P R Mahrer; R H Selzer; C R Liu Cr; C H Liu Ch; S P Azen Journal: Ann Intern Med Date: 2001-12-04 Impact factor: 25.391
Authors: E Seminari; A Pan; G Voltini; G Carnevale; R Maserati; L Minoli; G Meneghetti; C Tinelli; S Testa Journal: Atherosclerosis Date: 2002-06 Impact factor: 5.162
Authors: Patrick Mercié; Rodolphe Thiébaut; Valérie Lavignolle; Jean-Luc Pellegrin; Marie-Christine Yvorra-Vives; Philippe Morlat; Jean-Marie Ragnaud; Michel Dupon; Denis Malvy; Hélène Bellet; Sylvie Lawson-Ayayi; Raymond Roudaut; Françios Dabis Journal: Ann Med Date: 2002 Impact factor: 4.709
Authors: Eric C Seaberg; Lorie Benning; A Richey Sharrett; Jason M Lazar; Howard N Hodis; Wendy J Mack; Mark J Siedner; John P Phair; Lawrence A Kingsley; Robert C Kaplan Journal: Stroke Date: 2010-08-26 Impact factor: 7.914
Authors: Joseph A C Delaney; Rebecca Scherzer; Mary L Biggs; Michael G Shliplak; Joseph F Polak; Judith S Currier; Richard A Kronmal; Christine Wanke; Peter Bacchetti; Daniel O'leary; Phyllis C Tien; Carl Grunfeld Journal: AIDS Date: 2010-09-10 Impact factor: 4.177
Authors: Theodoros Kelesidis; Michelle A Kendall; Otto O Yang; Howard N Hodis; Judith S Currier Journal: J Infect Dis Date: 2012-10-12 Impact factor: 5.226
Authors: Robert C Kaplan; Lawrence A Kingsley; Stephen J Gange; Lorie Benning; Lisa P Jacobson; Jason Lazar; Kathryn Anastos; Phyllis C Tien; A Richey Sharrett; Howard N Hodis Journal: AIDS Date: 2008-08-20 Impact factor: 4.177